Waldron, Cherry-Ann ORCID: https://orcid.org/0000-0001-8465-2492, Thomas-Jones, Emma ORCID: https://orcid.org/0000-0001-7716-2786, Bernatoniene, Jolanta, Brookes-Howell, Lucy ORCID: https://orcid.org/0000-0002-8263-7130, Faust, Saul N, Harris, Debbie ORCID: https://orcid.org/0000-0002-7073-7724, Hinds, Lucy, Hood, Kerenza ORCID: https://orcid.org/0000-0002-5268-8631, Huang, Chao, Mateus, Céu, Pallmann, Philip ORCID: https://orcid.org/0000-0001-8274-9696, Patel, Sanjay, Paulus, Stéphane, Peak, Matthew, Powell, Colin, Preston, Jennifer and Carrol, Enitan D 2022. Biomarker-guided duration of Antibiotic Treatment in Children Hospitalised with confirmed or suspected bacterial infection (BATCH): protocol for a randomised controlled trial. BMJ Open 12 (1) , e047490. 10.1136/bmjopen-2020-047490 |
Preview |
PDF
- Published Version
Available under License Creative Commons Attribution. Download (2MB) | Preview |
Abstract
Introduction Procalcitonin (PCT) is a biomarker more specific for bacterial infection and responds quicker than other commonly used biomarkers such as C reactive protein, but is not routinely used in the National Health Service (NHS). Studies mainly in adults show that using PCT to guide clinicians may reduce antibiotic use, reduce hospital stay, with no associated adverse effects such as increased rates of hospital re-admission, incomplete treatment of infections, relapse or death. A review conducted for National Institute for Health and Care Excellence recommends further research on PCT testing to guide antibiotic use in children. Methods and analysis Biomarker-guided duration of Antibiotic Treatment in Children Hospitalised with confirmed or suspected bacterial infection is a multi-centre, prospective, two-arm, individually Randomised Controlled Trial (RCT) with a 28-day follow-up and internal pilot. The intervention is a PCT-guided algorithm used in conjunction with best practice. The control arm is best practice alone. We plan to recruit 1942 children, aged between 72 hours and up to 18 years old, who are admitted to the hospital and being treated with intravenous antibiotics for suspected or confirmed bacterial infection. Coprimary outcomes are duration of antibiotic use and a composite safety measure. Secondary outcomes include time to switch from broad to narrow spectrum antibiotics, time to discharge, adverse drug reactions, health utility and cost-effectiveness. We will also perform a qualitative process evaluation. Recruitment commenced in June 2018 and paused briefly between March and May 2020 due to the COVID-19 pandemic. Ethics and dissemination The trial protocol was approved by the HRA and NHS REC (North West Liverpool East REC reference 18/NW/0100). We will publish the results in international peer-reviewed journals and present at scientific meetings.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Medicine Centre for Trials Research (CNTRR) |
Additional Information: | This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. |
Publisher: | BMJ Publishing Group |
ISSN: | 2044-6055 |
Date of First Compliant Deposit: | 31 January 2022 |
Date of Acceptance: | 3 December 2021 |
Last Modified: | 09 Nov 2024 17:30 |
URI: | https://orca.cardiff.ac.uk/id/eprint/146943 |
Citation Data
Cited 5 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
Edit Item |